Rao J, Wu N, Qu X, et al. - Researchers conducted this retrospective observational study to explore the connection between pretreatment inflammation-based factors and outcomes in patients with macular edema secondary to retinal vein occlusion and its subtypes after intravitreal ranibizumab or conbercept implant. The sample consisted of individuals who were diagnosed with macular edema secondary to retinal vein occlusion at the First Affiliated Hospital of Nanchang University between January 2017 and January 2019, and who subsequently received intravitreal anti-vascular endothelial growth factor treatment. Three hundred fifteen treatment-naïve eyes treated with anti-VEGF drugs for RVO-ME have been retrospectively analyzed in this analysis. Higher pretreatment PLR was related to best-corrected visual acuity in RVO-ME patients and their subtypes who were treated with anti-VEGF medications. The PLR can be used as a predictive and prognostic method for successful management of intravitreal injection outcomes.